SEARCH RESULT

Total Matching Records found : 8452

Budget 2012 reinforces UIDAI’s existence-Harsimran Julka

Budget 2012 has further validated the existence of the Unique Identification Authority of India, whose identity was under question barely six months ago, by giving it more money and responsibilities to shape the government's technological interventions. The government has allocated the UIDAI Rs 1,758 crore from the Budget in 2012-13, a year-on-year increase of 47%, primarily to increase enrolments of Indians for unique IDs to 600 million, from 200 million.  A...

More »

A life saver-Shamnad Basheer

Compulsory licence can go a long way to ensure access to cheaper drugs In a momentous development, the Indian patent office issued the ever-compulsory licence in a highly contentious pharmaceutical patent case. The decision is a thumping victory for several patients and health activists who have been fighting what can only be labelled as highly inequitable pricing strategies by multinational drug firms for the past several decades. In August 2011, Natco, an...

More »

MGNREGA led to double digit growth in wages annually, exceeding rate of inflation

-The Pioneer Hitting at UPA’s biggest flagship scheme Mahatma Gandhi National Rural Employment Guarantee Act (MGNREGA), Agriculture Ministry has criticised the scheme in it’s first ever Agriculture Survey saying that MGNREGA has led to double digit growth in wages annually in the last few years even exceeding the rate of inflation that prevailed during this period. The Agriculture Survey is compiled by the Agriculture Ministry as a precursor to Union Budget on...

More »

A historic move to make drugs affordable-G Ananthakrishnan

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

More »

Oil firms’ losses on fuel sales may spike next fiscal-Utpal Bhaskar

Government-owned oil marketing companies (OMCs) may witness a 52% jump in losses on account of selling fuel below cost at state-mandated prices to Rs.2 trillion in the next financial year, said R.S. Butola, chairman, Indian Oil Corp. Ltd (IOC), the nation’s largest fuel retailer. Such an increase will impact the financials of government-owned OMCs such as IOC, Hindustan Petroleum Corp. Ltd (HPCL) and Bharat Petroleum Corp. Ltd (BPCL), which currently register...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close